News & Updates

Temporary interruption of adjuvant endocrine therapy (ET) to allow for pregnancy has demonstrated short-term safety, with no increase in risk of breast cancer events, including distant recurrence, in hormone receptor–positive breast cancer survivors who have completed 18–30 months of adjuvant ET.

The incidence of melanoma and nonmelanoma skin cancer appears to be markedly low among people with vitiligo, as reported in a study.

The 5-HT_2A receptor agonist psilocybin, when taken under medical supervision, may offer a promising approach to treatment of major depressive disorder (MDD) in cancer patients, results of a small phase II study suggest.

Patients who present with second primary melanomas have better survival and thinner lesions than those presenting with single primary melanomas, reveals a study.

Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.

Good quality surgery conferred a progression-free survival (PFS) benefit for women with ovarian sex cord stromal tumours (SCST) in the first-line setting and on first and second relapse. Chemotherapy, on the other hand, had no impact on survival in the first-line or relapse setting.